## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates). Caution: overbought RSI (71).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($126.13)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Precision oncology at your communityâ€™s doorstep**
- Source: Illumina | 20251208T151032 | Bullish | Relevance: 98%
-  Illumina is making comprehensive genomic profiling (CGP) testing more accessible to community cancer care centers. This allows in-house labs to utilize CGP, which assesses hundreds of genes and biomarkers, to improve therapeutic options and patient outcomes. The move aims to decentralize CGP testing, reducing turnaround times and operational barriers for local oncology practices.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 8 ($80.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (8 transactions in 90 days).
2. Overbought RSI (71) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +3.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 27.0x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Insider selling cluster ($80.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 6.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 27.0 |
| Current P/E | 28.6 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.9% to 4.5% (+3.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 77th percentile. MRS_5 at 3.2% confirms short-term momentum alignment. AM_20 at 7.1% shows strong absolute momentum above own 20MA. Outperforming sector by 8.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 71, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.50% (CS: 78) | Strong |
| RSI_14 | 70.8 | Overbought |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 1.071x | Above |
| vs SMA50 | 1.196x | Above |
| vs SMA200 | 1.415x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $134.91
- **Stop Loss:** $126.13 (6.5% risk)
- **Target:** $152.47 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $7,554.96
- **Portfolio %:** 7.55%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*